Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

February 5, 2027

Study Completion Date

February 5, 2028

Conditions
Resectable Pancreatic Adenocarcinoma
Interventions
DRUG

NALIRIFOX

Patient in upfront surgery arm will receive operation followed by adjuvant chemotherapy with NALIRIFOX; patient in experimental arm will receive neoadjuvant NALIRIFOX followed by operation than adjuvant NALIRIFOX after operation.

Trial Locations (9)

Unknown

RECRUITING

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

RECRUITING

China Medical University Hospital, Taichung

RECRUITING

Taichung Veterans General Hospital, Taichung

RECRUITING

National Cheng Kung University Hospital, Tainan City

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Taipei Veterans General Hospital, Taipei

RECRUITING

Tri-Service General Hospital, Taipei

RECRUITING

Linkou Chang Gung Memorial Hospital, Taoyuan District

All Listed Sponsors
collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

National Taiwan University Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

collaborator

Tri-Service General Hospital

OTHER

lead

Taichung Veterans General Hospital

OTHER